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Abstract
Diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are among the most aggressive B cell non-
Hodgkin lymphomas. Maternal embryonic leucine zipper kinase (MELK) plays a role in cancer cell cycle progression
and is associated with poor prognosis in several cancer cell types. In this study, the role of MELK in DLBCL and MCL
and the therapeutic potential of MELK targeting is evaluated. MELK is highly expressed in DLBCL and MCL patient
samples, correlating with a worse clinical outcome in DLBCL. Targeting MELK, using the small molecule OTSSP167,
impaired cell growth and survival and induced caspase-mediated apoptosis in the lymphoma cells. Western blot
analysis revealed that MELK targeting decreased the phosphorylation of FOXM1 and the protein levels of EZH2 and
several mitotic regulators, such as Cdc25B, cyclin B1, Plk-1, and Aurora kinases. In addition, OTSSP167 also sensitized
the lymphoma cells to the clinically relevant Bcl-2 inhibitor venetoclax by strongly reducing Mcl1 levels. Finally,
OTSSP167 treatment of A20-inoculated mice resulted in a significant prolonged survival. In conclusion, targeting MELK
with OTSSP167 induced strong anti-lymphoma activity both in vitro and in vivo. These findings suggest that MELK
could be a potential new target in these aggressive B cell malignancies.
Introduction
Non-Hodgkin lymphoma (NHL) is the most common
hematological cancer, with diffuse large B cell lymphoma
(DLBCL) and mantle cell lymphoma (MCL) among the
most aggressive subtypes. Within the DLBCL subtype,
different molecular subgroups are distinguished based
upon the cell of origin, including Activated B cell (ABC)-
and Germinal Center B cell (GCB)-DLBCL1,2. ABC-
DLBCL has a worse clinical outcome compared with
GCB-DLBCL2. Recently, a new distinct entity with poor
prognosis was described as “the double/triple hit lym-
phomas”, with rearrangements of MYC and BCL-2 and/or
BCL-6. In addition, patients with high expression of both
Myc and Bcl-2, but lacking the identifiable rearrange-
ments (called “double expressers”) also have a poor
prognosis3. The standard-of-care treatment in these
aggressive NHLs consists of the R-CHOP regimen
(rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone). However, 30% of DLBCL patients and
almost all MCL patients still relapse1,4. Therefore, inves-
tigation and development of new strategies are still
required.
Maternal embryonic leucine zipper kinase (MELK), also
known as pEg3 or murine protein K38 (MPK38), is a
serine/threonine protein kinase that plays a role in several
biological processes, such as stem cell phenotypes, mitotic
progression, apoptosis, and tumorigenesis5–7. It has been
suggested that MELK regulates the G2/M transition, by
phosphorylating proteins that regulate G2/M cell cycle
progression8. MELK is able to phosphorylate and activate
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the transcription factor FOXM1, which drives expression
of several mitotic regulatory proteins, including Aurora
kinases, cyclin B1, and Survivin8,9. Cdc25B, which is an
activator of Cdk1 in early mitosis, can also be phos-
phorylated and activated by MELK10–12. In addition,
enhancer of zeste homolog 2 (EZH2), c-Jun, p53, apop-
tosis signal-regulating kinase 1 (ASK1), DEPDC1, and
SOX2 are also targets of MELK5,7,13. Several studies
observed high MELK levels in different types of cancer
and MELK overexpression is often associated with a poor
prognosis6,7,14–18. Moreover, knockdown studies resulted
in decreased survival of cancer cells19,20. The implication
of MELK in tumor growth makes it an attractive ther-
apeutic target for cancer therapy7. OTSSP167 is a potent
MELK inhibitor and was shown to impair cancer growth
in leukemia, myeloma, small cell lung cancer, neuro-
blastoma, prostate cancer, and kidney cancer cells15,18,21–24.
As such, OTSSP167 is currently tested in different clinical
trials in patients with solid tumors and refractory
and relapsed leukemia25. In this study, the clinical rele-
vance of MELK and the therapeutic potential of the
MELK inhibitor OTSSP167 was investigated in DLBCL
and MCL.
Materials and methods
Analysis of MELK gene expression levels
The publicly available gene expression profiling (GEP)
datasets with gene expression data and survival data of
183 GCB-DLBCL patients, 167 ABC-DLBCL patients and
64 unclassified DLBCL patients (GSE10846)26,27, gene
expression data of 33 B cell samples, 23 ABC-DLBCL
patients, 29 GCB-DLBCL patients, and 3 unclassified
DLBDL patients (GSE56315)28, gene expression data of 7
indolent and 15 aggressive MCL patients (GSE16455)29,
and gene expression data of 13 human DLBCL cell lines
and 5 MCL cell lines (GSE36133)30 were used. To mini-
mize batch effects from the different experiments, raw
CEL files were obtained from the Gene Expression
Omnibus (GEO) and GCRMA-normalization on pooled
CEL files was performed in R using bioconductor packa-
ges oligo and affy31,32. The following probeset was used:
204825-at.
Patient biopsies and staining
Patient samples were collected at the Department of
Biopathology in Montpellier (CHU Montpellier, France).
Three-μm-thick sections from tissue microarrays con-
taining three representative 0.6-mm cores of routinely
processed tissues from 27 DLBCL patients treated with R-
CHOP were included33. The quality of each tissue core
was evaluated based on its morphology, using hematox-
ylin and eosin staining, and the percentage of CD20+
tumor cells. Only tissue cores with more than 50% CD20+
tumor cells were retained for immunohistochemical
analysis. All samples were stained with MELK antibody
(Sigma-Aldrich, Bornem, Belgium) using the automated
immunostainer Benchmark XT (Roche Ventana, Basel,
Switzerland). In addition, a CD20 staining was performed
on consecutive slides. As a positive control, tonsils with
secondary follicles were used. Immunostaining results
(i.e., percentage of positive cells) were evaluated by an
expert pathologist. The percentage of tumor cells with a
staining of any intensity was determined at a magnifica-
tion ×400 on a Leica DM2000 microscope. The counting
was performed in hot-spot areas by means of an ocular
grid. Patients were divided into good and poor prognosis
groups based on the validated revised International
Prognostic Index (R-IPI) score of the DLBCL patients.
The study protocol was approved by the ethics committee
of Montpellier and the informed consent was obtained
from all subjects (DC-2013-2027).
Cell culture
The human GCB-DLBCL cell lines SU-DHL-6, OCI-
Ly1, and OCI-Ly7 were maintained in IMDM medium
(Life Technologies) supplemented with 10% fetal calf
serum (FCS) (Biochrom AG, Berlin, Germany) and 2mM
glutamine (Life Technologies, Gent, Belgium). ABC-
DLBCL (U2932 and RI-1) and MCL cell lines (Jeko-1,
Mino and Rec-1) were maintained in RPMI-1640 medium
(Lonza, Basel, Switzerland) supplemented with 10% FCS
and 2mM glutamine. The murine DLBCL cell line (A20)
was maintained in supplemented RPMI-1640 medium
with 0.05 mM β-mercapto-ethanol (Sigma-Aldrich). Cells
were cultured at 37 °C in a humidified 5% CO2 atmo-
sphere. All cell lines were obtained from ATCC and
regularly tested for mycoplasma contamination and
checked for authenticity by STR profiling.
Reagents
The MELK inhibitor OTSSP167 was obtained from
MedChem Express (Bio-Connect, Huissen, The Nether-
lands). Venetoclax and rituximab were obtained from
Selleckchem (Bio-Connect) and doxorubicin hydro-
chlorate was purchased from Sigma-Aldrich. All agents
were dissolved in DMSO for in vitro studies and
OTSSP167 (hydrochloride) was dissolved in 5% glucose
for the in vivo experiment.
Quantitative real-time PCR
Total RNA was extracted using the Nucleospin RNA
plus kit (Macherey-Nagel, Düren, Germany) and reverse
transcription was performed using the Verso cDNA
synthesis kit (ThermoFisher Scientific, Gent, Belgium),
both according to manufacturer’s instructions. Quantita-
tive real-time PCR was performed as previously descri-
bed34. Primers for MELK were purchased from IDT
(Leuven, Belgium) and primers for GAPDH were
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purchased from Qiagen (Venlo, The Netherlands). Primer
sequences for MELK were as followed (5′–3′): forward:
GTG CTA GAG ACA GCC AAC AA; reverse: CAG GCG
ATC CTG GGA AAT TA.
Western blot analysis
Cells were harvested, lysed and western blot was per-
formed as previously described34. Antibodies were used
against MELK (#2274), Aurora B kinase (#3094), cyclin B1
(#4138), pFOXM1 (#14170), EZH2 (#4905), Cdc25B
(#9525), Plk-1 (#4535), Aurora A kinase (#3092), PARP
(#9542), Mcl1 (#5453), pBcl-2 (#2827), Bcl-xL (#2764),
caspase-3 (#9662) and β-actin (#4967) (all from Cell Sig-
naling Technology, Leiden, the Netherlands) and FOXM1
(sc_376471), Bcl-2 (sc_492) and pBcl-xL (sc_101644)
(Santa Cruz, Heidelberg, Germany). Quantification of the
different protein levels was performed in Image J,
according to manufacturer’s instructions.
Cell viability assay
The CellTiter-Glo Luminiscent Viability assay (Pro-
mega, Leiden, The Netherlands) was used to measure cell
viability according to manufacturer’s instructions.
100,000 cells/ml were treated with the indicated agent and
cell viability was measured after 48 h.
Apoptosis assay
100,000 cells/ml were treated with the indicated agent
(s) and apoptosis was measured after 48 h. Cells were
harvested and apoptosis was quantified using an
Annexin V/7’-AAD staining (BD Biosciences, Franklin
Lakes, USA) and active caspase-3 staining (BD Bios-
ciences), according to manufacturer’s instructions. Cells
were analyzed by flow cytometric analysis (FACS Canto,
BD Biosciences).
BrdU cell proliferation assay
The BrdU Cell Proliferation Assay Kit (Cell Signaling
Technology) was performed according to manufacturer’s
instructions. 100,000 cells/ml were treated with the indi-
cated agent for 24 h and the BrdU cell proliferation assay
was performed after 3 h of BrdU labeling.
Cell cycle analysis
100,000 cells/ml were treated with the indicated agent
and cell cycle analysis was performed after 24 h. Propi-
dium iodide (PI) staining was used to analyze cell cycle
distribution. Cells were harvested and incubated for
10min with a PI solution containing 1mg/ml sodium
nitrate (Merck KGaA, Darmstadt, Germany), 0.1% Triton-
X (Merck), 100 μg/ml RNase A (Boehringer, Ingelheim,
Germany), and 50 μg/ ml PI (Sigma-Aldrich). Cells were
analyzed by flow cytometry.
In vivo experiment
Female BALB/c mice were purchased from Charles
River (Ecully, France). They were housed and maintained
following the conditions approved by the Ethical Com-
mittee for Animal Experiments, Vrije Universiteit Brussel
(license no. LA1230281, CEP no. 18-231-4). Mice were
subcutaneously inoculated with 1 × 106 A20 cells in the
right flank as previously described35. When tumors were
palpable, mice were treated three times a week via intra-
venous injection with OTSSP167 (10 mg/kg). Mice were
sacrificed when the tumor reached a maximum volume of
1500 mm³. Tumor volume was calculated as followed:
volume (mm³)= (length × width²)/2.
Statistical analysis
Prognostic significance of MELK gene expression was
calculated using the MaxStat R package. Statistical dif-
ferences in overall survival was calculated by a log-rank
test and survival curves were plotted using Kaplan–Meier
method. Graphical and statistical analysis was performed
using GraphPad Prism 5.01 software. Statistical sig-
nificance (p-value of p < 0.05 was considered significant)
was determined by a Mann–Whitney U-test (to compare
two groups) and a one-way ANOVA with Bonferonni
correction for multiple testing.
Results
MELK expression is upregulated in DLBCL and MCL,
correlating with a poor survival in DLBCL
The potential clinical relevance of MELK in the
aggressive lymphomas DLBCL and MCL was assessed
using publicly available GEP datasets. MELK mRNA
expression was examined using GEP data from B cell
samples (n= 33), GCB-DLBCL (n= 212), ABC-DLBCL
(n= 190), and unclassified DLBCL patients (n= 67). As
shown in Fig. 1a, MELK expression was significantly
increased in all DLBCL subtypes compared with normal B
cell samples. Moreover, high MELK expression levels
were associated with a significant worse survival in
DLBCL patients (93 ABC-, 108 GCB-, and 32 unclassified
DLBCL patients) receiving R-CHOP treatment (Fig. 1b).
GEP data from naive B cells (n= 6), indolent MCL (n=
7), and aggressive MCL patients (n= 15) were used to
investigate the MELK expression in MCL patients. Ana-
lysis of MELK mRNA expression in this MCL patient
cohort revealed that both indolent and aggressive MCL
primary samples have significant higher levels of MELK
compared with the naive B cell samples (healthy coun-
terparts of MCL cells36), with no significant difference in
MELK mRNA expression between indolent and aggres-
sive MCL patients (Fig. 1c).
Next, the prognostic value of MELK expression in
DLBCL patients was examined. The protein expression of
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MELK was determined in a small patient cohort of
DLBCL patient treated with R-CHOP (Fig. 1d). The per-
centage of MELK positive lymphoma cells was plotted
against the patient’s prognosis according to their R-IPI.
The trend of associating a poor prognosis and a higher
amount of MELK positive cells is observed (Fig. 1e).
Pharmacological inhibition of MELK using OTSSP167
induces apoptosis
To investigate MELK as a potential target in human
DLBCL and MCL cell lines, MELK expression was first
assessed in the GEP data of a large panel of human
DLBCL and MCL cell lines. Significant higher MELK
mRNA expression was observed in all DLBCL and MCL
cell lines compared with the B cell samples (Supplemental
Fig. 1A). These observations were also confirmed in a
select panel of human DLBCL (both ABC- and GCB-
subtype) and MCL cell lines, both at mRNA and protein
levels (Supplemental Fig. 1B–C).
The effect of the pharmacological MELK inhibitor
OTSSP167 was then investigated in the selected human
DLBCL and MCL cell lines. First, the effect of the MELK
inhibition on lymphoma cell viability was assessed. A
dose-dependent decrease in viability was observed in all
cell lines after 48 h of OTSSP167 treatment with an IC-50
value around 15 nM for most of the DLBCL cell lines,
except for the RI-1 cells and SU-DHL-6 cells (Fig. 2a and
Supplemental Table 1A). The ABC-DLBCL cell line RI-1
was found the most sensitive (IC-50 ≈ 6 nM), while the
GCB-DLBCL cell line SU-DHL-6 was the least sensitive
(IC-50 ≈ 30 nM). Among the MCL cell lines, the Mino
and the Rec-1 cells were, respectively, the most sensitive
Fig. 1 MELK mRNA expression is increased in DLBCL and MCL patients, which is associated with poor survival in DLBCL. a MELK gene
expression levels of B cell samples (n= 33), patients with ABC-DLBCL (n= 190), patients with GCB-DLBCL (n= 212) and patients with unclassified
DLBCL (n= 67) were obtained from the publicly available microarray datasets GSE10846 and GSE56315. Mean expression ± SD is shown in red.
***p < 0.001. b The prognostic value of MELK was determined in DLBCL patients (93 ABC, 108 GCB, and 32 unclassified DLBCL patients) receiving R-
CHOP treatment from the Lenz cohort (n= 233) using Maxstat analysis (cut-off value used is 9.17). c MELK gene expression levels of patients with
indolent (n= 7) and aggressive MCL (n= 15) were obtained from the GSE16455 dataset. Mean expression ± SD is shown in red. *p < 0.05 and
**p < 0.01. d Immunohistochemical analysis of MELK expression in a DLBCL patient. A ×4 and ×20 magnification is shown. e Percentage of MELK
positive lymphoma cells was counted in 27 DLBCL patients treated with R-CHOP and plotted against the estimated prognosis according to the
R-IPI-score of the patients.
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(IC-50 ≈ 13 nM) and the least sensitive (IC-50 ≈ 25 nM).
Importantly, no clear correlation between MELK protein
expression and OTSSP167 sensitivity nor between the
doubling time and OTSSP167 sensitivity was found
(Supplemental Table 1, B–C). Then, the effect of MELK
inhibition was determined on apoptosis by an Annexin V/
7’-AAD and active caspase-3 staining. Consistent with the
viability data, a dose-dependent increase in apoptotic cells
was observed in all cell lines after 48 h of OTSSP167
treatment, which was associated with an increase in the
amount of caspase-3-positive cells (Fig. 2b, c). In addition,
western blot analysis demonstrated that OTSSP167
treatment resulted in a clear increase in cleaved poly
ADP-ribose polymerase (PARP) protein levels after 48 h
(Fig. 2d). Importantly, western blot analysis also con-
firmed the on-target effect of OTSSP167 as evidenced by
clear reduction in MELK protein levels in the GCB-
DLCBL cell line SU-DHL-6, the ABC-DLBCL cell line
U2932 and the MCL cell line Jeko-1 and in Aurora B
kinase protein levels in U2932 and Jeko-1 cells (Fig. 2e).
OTSSP167 treatment affects lymphoma cell cycle
progression
Since MELK has been shown to be involved in G2/M
progression8, the effect of OTSSP167 on lymphoma cell
proliferation was next evaluated using a BrdU incorporation
Fig. 2 MELK inhibition, using OTSSP167 treatment, reduces lymphoma cell viability and induces caspase-mediated apoptosis. a–c DLBCL
and MCL cell lines were treated for 48 h with OTSSP167 (3.125, 6.25, 12.5, 25, and 50 nM). The effect on viability was determined using a CellTiter-Glo
assay (a). Results are shown as % viability relative to control. Results shown are mean ± SD of three independent experiments. The effect on apoptosis
was determined using an Annexin V/7’-AAD staining followed by flow cytometric analysis (b). Percentage apoptotic cells are the sum of the
percentage Annexin V and Annexin V/7’-AAD positive cells. Results shown are mean ± SD of three independent experiments. The percentage of
caspase-3-positive cells was determined using active caspase-3 staining followed by flow cytometry analysis (c). Results shown are mean ± SD of
three independent experiments. *p < 0.05 (d, e). Expression of PARP (d), MELK (e), and Aurora B kinase (AurB, e) was determined after 48 h of 25 nM
OTSSP167 treatment using western blot. β-actin was used as loading control. One experiment representative of 3 is shown.
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assay. OTSSP167 treatment resulted in less proliferating
DLBCL and MCL cells (Fig. 3a). Further examination of cell
cycle progression revealed that OTSSP167 treatment
resulted in a significant increase in the amount of cells in
both subG1 and G2/M phase after 24 h (Fig. 3b). Together
these data indicate that MELK also plays an important role
in cell cycle progression in DLBCL and MCL and inhibition
of MELK results in a prolonged G2/M phase.
To determine the underlying mechanism of action, the
effect of OTSSP167 on the downstream targets (FOXM1,
Cdc25B, and EZH2) was assessed by western blot. As
shown in Fig. 3c, 24 h of OTSSP167 treatment strongly
reduced the phosphorylation of FOXM1, while the total
FOXM1 protein levels remained more or less stable.
Moreover, Cdc25B and EZH2 protein levels were also
strongly reduced in the OTSSP167-treated cells compared
with the untreated samples. Since pFOXM1 is the acti-
vated transcription factor that regulates the expression of
several mitotic regulators, the protein levels of cyclin B1,
Aurora A kinase and Polo-like kinase 1 were also
Fig. 3 OTSSP167 treatment affects lymphoma cell cycle progression. a Proliferating lymphoma cells were incubated for 24 h with OTSSP167
(6.25, 12.5, and 25 nM) and subsequently with BrdU for 3 h and analyzed using the BrdU proliferation assay kit. Results shown are mean ± SD of three
independent experiments. *p < 0.05. b Cell cycle analysis was performed after 24 h of OTSSP167 treatment (12.5 and 25 nM) using PI staining. Results
shown are mean ± SD of three independent experiments. *p < 0.05 and **p < 0.01. c Protein levels of (p)FOXM1, Cdc25B, Cyclin B1, Aurora A kinase
(AurA), Plk-1, and EZH2 were determined in DLBCL and MCL cell lines after 24 h of 25 nM OTSSP167 treatment. β-actin was used as loading control.
One experiment representative of 3 is shown. d Scheme of the most examined downstream targets of MELK inhibition in cancer. Green arrows
indicate activation and red arrows indicate inhibition/suppression. There is still some controversy whether MELK activates or inhibits p53 (AUR B:
Aurora B kinase, CENP A/B: centromere protein A/B).
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analyzed. Consistent with the reduced pFOXM1 levels,
OTSSP167 treatment also decreased the protein levels of
cyclin B1, Aurora A kinase, and Polo-like kinase 1 in all
cell lines (Fig. 3c, d and Supplemental Fig. 2).
OTSSP167 treatment reduces tumor growth in vivo and
prolongs overall survival
To validate the anti-lymphoma activity of OTSSP167
in vivo, the A20 syngeneic immunocompetent model of
murine lymphoma was used. First, the sensitivity of the
murine A20 lymphoma cells was evaluated in vitro. Con-
sistent with the human cell lines, a dose-dependent decrease
in viability and increase in apoptotic cells was observed after
48 h (Supplemental Fig. 3A–B). Next, 8-week-old Balb/c
mice were subcutaneously inoculated with A20 lymphoma
cells and when the tumor was palpable the OTSSP167
treatment started (Fig. 4a). The tumor volume (mm³) was
assessed over time during this survival study. A significant
difference in the tumor volume between vehicle-treated and
OTSSP167-treated mice was already seen after 1 week of
treatment (Fig. 4b). Moreover, all vehicle mice reached the
maximum tumor volume within 34 days after inoculation,
whereas OTSSP167-treated mice reached the maximum
volume 56 days after inoculation (Fig. 4b and Supplemental
Fig. 3C–D). This delay in tumor growth also correlated with
a significant better survival for OTSSP167-treated mice
compared with vehicle-treated mice (Fig. 4c). Western blot
analysis confirmed that OTSSP167 treatment significantly
reduced the MELK protein expression in samples obtained
from the treated mice compared with vehicle mice (Fig. 4d),
while no effect was seen on Aurora B kinase protein levels.
Of note, the total body weight of the mice was not affected
by the OTSSP167 treatment, suggesting that OTSSP167 is
not toxic for the mice (Supplemental Fig. 3E).
Combining OTSSP167 with venetoclax leads to a
synergistic anti-lymphoma effect
Finally, OTSSP167 was combined with the standard-of-
care agents doxorubicin and rituximab and the novel,
selective Bcl-2 inhibitor venetoclax. Sub-optimal con-
centrations (IC-10, IC-30, and IC-50) of the agents were
used to test their combinatory effect (Supplemental Table
2). OTSSP167 treatment did not significantly enhance the
anti-lymphoma activity of doxorubicin nor rituximab in all
lymphoma cell lines tested (Supplemental Fig. 4A–B). In
contrast, OTSSP167 treatment was found to significantly
and synergistically sensitize lymphoma cells of all subtypes
tested to venetoclax-mediated cell death and this both at
high and low concentrations (Fig. 5a). Next, the underlying
mechanisms of action of the combination treatment was
evaluated by western blot. As shown in Fig. 5b, a clear
reduction in MELK and Mcl1 protein levels was observed in
all DLBCL and MCL cell lines used after OTSSP167
treatment. No consistent differences were observed in (p)
Bcl-2 and (p)Bcl-xL protein levels. Importantly, the com-
bination of venetoclax and OTSSP167 also induced more
apoptosis compared with both single agents, as evidenced
by a further increase in the levels of cleaved caspase-3.
Together, these data provide evidence that OTSSP167
treatment reduces Mcl1 protein levels, thereby sensitizing
the lymphoma cells to venetoclax.
Discussion
Despite the current improvements in the anti-
lymphoma therapy, there is still a poor survival in one-
third of the DLBCL patients and no difference is observed
in overall survival of MCL patients2,37. Thus, it remains
necessary to improve anti-lymphoma therapy. In this
study, MELK is identified as a novel target in the
aggressive lymphomas DLBCL and MCL. As described
above, increased MELK expression was already reported
in a variety of solid (breast, prostate, etc.) and hemato-
logical cancers (leukemia and multiple myeloma), and has
been associated with a worse clinical outcome for these
patients6,14–18. Consistent with these reports, MELK gene
expression was also found significantly elevated in all
DLBCL and MCL subtypes compared with their normal
counterparts. Moreover, high MELK mRNA expression
correlates with poor survival outcome in DLBCL patients.
The data from our discovery cohort of 27 DLBCL patients
suggest that high MELK protein expression could also be
linked to a poor prognosis in DLBCL patients treated with
R-CHOP. However, only a trend in differential MELK
expression was observed in this small cohort; with only six
patients having a poor prognosis according to the R-IPI
scoring system. Further validation in a prospective study
in larger patient cohorts thus remains warranted. Toge-
ther, these data suggest that MELK could play a role in
DLBCL and MCL pathogenesis, supporting the preclinical
testing of MELK as novel target for DLBCL and MCL.
Targeting MELK in different cancer cell types, using
either siRNA knockdown or pharmacological inhibition,
resulted in an impaired tumor growth by inducing apop-
tosis and/or decreasing cell proliferation both in vitro and
in vivo11,15,17–24. Several agents were already used to target
MELK, such as MELK-T138, MELK-8a39, MELK-IN-140,
and OTSSP16741. In our study OTSSP167 was used, since it
is a potent MELK inhibitor that fits effectively into the
active site of the kinase and is currently the only one under
investigation in clinical trials25,42. Consistent with the pre-
vious studies in cancer, OTSSP167 reduces lymphoma cell
viability in a dose-dependent manner and was able to
induce caspase-3-mediated apoptosis. In addition, a dose-
dependent decrease in cell proliferation is observed after
OTSSP167 treatment, correlating with a prolonged G2/M
phase in DLBCL and MCL. The anti-lymphoma activity of
OTSSP167 was also validated in vivo using the murine A20
lymphoma model. A significant reduction in tumor growth
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was observed after OTSSP167 treatment, which was asso-
ciated with a significant better overall survival of the
OTSSP167-treated mice.
OTSSP167 has been described to inhibit MELK by
blocking autophosphorylation of MELK, thus resulting in
the degradation and loss of MELK protein13. It has also
been described that OTSSP167 can have off-target effects
on Aurora B kinase8. Accordingly, a clear decrease in
MELK protein levels was observed in DLBCL and MCL
cells after 24 h of OTSSP167 treatment. The protein levels
of Aurora B kinase were also reduced, however, to a lesser
extent. These findings were also confirmed in vivo, where
MELK protein levels are again more affected by
OTSSP167 treatment than Aurora B kinase protein levels.
Concerning the underlying mechanisms, it was reported
previously that both p53-dependent and p53-independent
upregulation of p21 is an important part of the
OTSSP167-induced apoptosis7,12,13,43. Moreover, it has
recently been described that MELK interacts with the
transcription factor FOXM1 (a master regulator for cell
proliferation) in a Plk-1-dependent manner and that
EZH2-mediated radiation resistance occurs through a
MELK-FOXM1-dependent manner in glioblastoma
cells9,44. FOXM1, Plk-1, and EZH2 are all described as
interesting therapeutic targets in both DLBCL and MCL,
and high expression of these genes is reported to be
associated with poor survival in lymphoma patients45–48.
Here it is shown that inhibiting MELK by OTSSP167 in
DLBCL and MCL cells also causes a decrease in phos-
phorylation of FOXM1 and subsequent downregulation of
the mitotic regulators Aurora A kinase, cyclin B1, Plk-1,
and Cdc25B. The downregulation of these mitotic
Fig. 4 OTSSP167 treatment reduces tumor growth in vivo and prolongs overall survival. a Balb/c mice were inoculated with murine A20
lymphoma cells and when tumor was palpable the mice were treated with OTSSP167 (10 mg/kg). Mice were sacrificed when tumor volume reached
1500mm³. b Evaluation of the tumor volume of vehicle (n= 11, red) and OTSSP167-treated mice (n= 11, green). *p < 0.05, **p < 0.01, and ***p <
0.001. c Survival curve of vehicle (red) and OTSSP167-treated mice (green). d Expression of MELK and Aurora B kinase (AurB) was determined in
samples from vehicle and OTSSP167-treated mice. β-actin was used as loading control. Quantification was performed with Image J.
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regulators can explain the observed prolonged G2/M
phase after OTSSP167 treatment. In addition, EZH2 is
also inhibited by the OTSSP167 treatment. In contrast to
previous studies, no upregulation of p21 protein levels
and no differences in p53 and phoshpo-p53 protein levels
were observed (data not shown). However, loss of p53
appears to occur frequently in DLBCL patients49. The
lymphoma cell lines used in this study are also char-
acterized by either TP53 mutations or loss of expression
of p5350,51, hence explaining the indifference in (phospho-)
p53 protein levels after MELK inhibition. Consistent with
our data, a study in p53-mutated myeloma cells also
failed to observe an increase in p21 after OTSSP167
treatment52. Moreover, there is still some controversy
whether the MELK-p53 interaction is pro- or anti-
apoptotic in cancer cells. Several studies showed that
MELK expression increases p53 activation, while others
demonstrated an inverse correlation between MELK
expression and p53 expression7. Since OTSSP167 is able
to inhibit the expression and centrosome localization of
Aurora B kinase, abrogation of the mitotic checkpoint (or
spindle assembly checkpoint) could be an alternative
mechanism of cell death by OTSSP167 treatment8.
However, this remains to be confirmed in future studies.
Fig. 5 Combining OTSSP167 with venetoclax leads to a synergistic anti-lymphoma effect. a Apoptosis of OTSSP167 (ots) and venetoclax-
treated SU-DHL-6, U2932, and Jeko-1 cells was determined after 48 h using an Annexin V/7’AAD staining followed by flow cytometry analysis. The
sum of the percentage Annexin V and Annexin V/7’AAD positive cells are shown. Results shown are mean ± SD of four independent experiments.
Each combination was compared with both single agents. ***p < 0.001 and combination indexes (CI) are shown. b Protein levels of MELK, (p)Bcl-2, (p)
Bcl-xL, Mcl1, and caspase-3 were determined in DLBCL and MCL cell lines after 24 h of OTSSP167 treatment in combination with venetoclax. SU-DHL-
6, U2932, and Jeko-1 cells were treated with, respectively, 30 nM OTSSP167 and 100 nM venetoclax, 15 nM OTSSP167 and 4.5 nM venetoclax, and
15 nM OTSSP167 and 500 nM venetoclax. β-actin was used as loading control. One experiment representative of 3 is shown.
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To further improve the anti-lymphoma activity of
OTSSP167, in vitro combination studies were performed.
Previously, studies in multiple myeloma and breast cancer
demonstrated that combining OTSSP167 with standard-of-
care agents (including lenalidomide, pomalidomide, and
bortezomib) could increase the anti-cancer effect of the
standard-of-care agent18,53. A promising novel agent in
clinical development in DLBCL and MCL is the selective
Bcl-2 inhibitor venetoclax (also known as ABT-199). Bcl-2
seems to play a crucial role in the pathogenesis of these
lymphomas justifying the use of venetoclax54. Although
venetoclax demonstrated low single agent effects in clinical
trials with B cell lymphomas, combination regimen (such as
venetoclax and ibrutinib in refractory MCL or venetoclax
and R-CHOP in DLBCL) suggest promising efficacy and
good tolerability54,55. Mcl1 is considered a major determi-
nant of resistance to venetoclax and Bolomsky et al. recently
demonstrated that OTSSP167 treatment reduces the Mcl1
protein levels in MM cells18,56. Therefore, we hypothesized
that OTSSP167 might sensitize the lymphoma cells to
venetoclax by reducing Mcl1 levels. Consistent with this
hypothesis, combining OTSSP167 with venetoclax sig-
nificantly and highly synergistically enhances the anti-
lymphoma effects of the MELK inhibitor in all cell lines
tested, even in the highly venetoclax-sensitive ABC-DLBCL
cell line U2932. Western blot analysis furthermore con-
firmed the reduction in Mcl1 protein levels in both
OTSSP167 and combo treated cells and the further increase
in cleaved caspase-3 levels in the combo treated cells.
Importantly, it has been reported that a concentration of
1 μM venetoclax corresponds to the clinically recom-
mended dose of 400mg per day in patients57,58. For our
in vitro combination experiments, we used sub-optimal
concentrations of venetoclax well below 1 μM. This
underlines the clinical relevance of our combination
experiments. Since MELK inhibition in breast cancer was
shown to activate the ATM-CHK2 pathway and thus sug-
gested to reactivate the DNA damage response, we expec-
ted that combining OTSSP167 with doxorubicin would
enhance the anti-lymphoma activity of this topoisomerase II
inhibitor38. However, our data did not demonstrate any
additional effect in DLBCL or MCL. A possible explanation
could be the use of a different MELK inhibitor. In the
former study MELK-T1 was used. This inhibitor was shown
to induce a S phase arrest instead of the G2/M phase arrest
observed here. Finally, OTSSP167 also failed to enhance the
anti-lymphoma effect of the anti-CD20 monoclonal anti-
body rituximab. This might be explained by the minor
cytotoxic effects that rituximab monotherapy had on the
lymphoma cell lines in vitro.
In conclusion, our data show that high MELK expres-
sion is associated with poor prognosis in the aggressive B
cell malignancy DLBCL. Targeting MELK using the small
molecule OTSSP167 resulted in a downregulation of the
mitotic regulators Cdc25B, cyclin B1, and Aurora kinases,
resulting in a prolonged G2/M phase. Moreover,
OTSSP167 demonstrated potent in vitro and in vivo anti-
lymphoma activity, which was further enhanced by the
Bcl-2 inhibitor venetoclax. These results therefore suggest
MELK as a potential new target in the aggressive B cell
lymphomas DLBCL and MCL, and support clinical testing
of OTSSP167 in these cancers.
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